history

This Month in Psychedelics - November 2022

Policy

The 2022 midterm elections caused November to be a monumental month for drug policy developments in the United States. While not every attempted effort was passed, many were successful. Kicking things off, Colorado voters approved a statewide measure to decriminalize natural psychedelics and create a model to legally purchase them. These changes will roll out gradually over the course of the next four years.

With nearly 70% of Americans in favor of legalizing cannabis, it’s no surprise that there were several victories in reforming cannabis policies across the country. Maryland and Missouri both legalized marijuana, becoming the 20th and 21st states to do so. Meanwhile, voters in Ohio, Wisconsin, and Texas approved a variety of cannabis-related drug policy reforms.

In addition to the midterm elections, bipartisan lawmakers in Congress formed a new first-of-its-kind “psychedelic caucus” which will “focus on exploring psychedelic research to alleviate the U.S. mental health crisis.” The congressional Psychedelics Advancing Clinical Treatments (PACT) caucus will not be advocating for drug policy reforms but will instead focus congressional conversations around the therapeutic potential of psychedelics and work toward educating lawmakers and the public.

Across the pond, the Netherlands is planning to ban nitrous oxide due to concerns that the drug will cause severe health issues in addition to the thousands of vehicular crashes the country has been experiencing between 2018 and 2021. The Dutch government is expected to confirm the ban on distribution, sale, and possession of nitrous oxide in January.

Industry

A psychedelic entrepreneur in Florida opened an above-board shroom dispensary. Well, sort of… rather than selling psilocybin mushroom products, the hemp dispensary is selling Amanita muscaria, the red-and-white dotted mushroom species that engenders psychoactive effects when consumed. This is yet another example of newly-formed businesses operating in legal gray areas involving psychoactive drugs, and it will be interesting to see if the shop is able to stay open now that word has spread about its trippy offerings.

Research

The final participant in the Multidisciplinary Association for Psychedelic Studies (MAPS) Phase 3 trial of MDMA-assisted therapy for PTSD completed their last session in the clinical treatment protocol, bringing the study to a close. The next step in the process will be an FDA evaluation of the treatment’s safety and efficacy, which will take place next year. It’s been a long ride for MAPS, which started the work of obtaining FDA approval to use MDMA therapeutically 36 years ago!

Compass Pathways published results from its Phase 2 clinical trial of psilocybin-assisted therapy for depression, and they left a little to be desired. Although the treatment yielded rapid antidepressant effects for most patients, only about 20% of participants still showed significant improvement at 12 weeks. These results are roughly as effective as existing SSRIs or traditional therapeutic treatments for depression like cognitive behavioral therapy.

A couple studies looking into ayahuasca found that the South American brew causes adverse side effects, but the benefits still outweigh the risks. This seems to me to be common sense, because the use of practically all psychedelics involves some negative side effects but as they say, “the juice is still worth the squeeze” in my opinion.

Harm Reduction

A survey analyzed responses from about 250,000 festival attendees and found that drug checking services create a safer environment. The study focused on both positive and negative impacts of on-site drug checking and concluded that not only did the service not result in an increase of drugs at festivals, but about 61% of people who used them disposed of drugs they were intending to take if they were unsure what they contained. In addition, the seven festivals that provided drug checking services did not incur a single drug-related death.

Miscellaneous

The U.S. National Park Service (NPS) issued a warning asking people to not lick toads that secrete 5-MeO-DMT, a psychedelic alkaloid present in the Sonoran desert toad. This messaging appears to have been shared even though there hasn’t been a noted increase in toad-licking happening in national parks. Besides, every psychonaut worth their salt knows that you don’t lick the toad, you smoke the extracted secretion! Nonetheless, it’s entertaining to see the U.S. government attempt to communicate with the public about psychedelic drugs, even if they aren’t getting all of the details right.

Wrapping up this month’s recap is a study of ancient human remains that found that a Nazca child consumed San Pedro cactus prior to being sacrificed in a ritual ceremony more than a thousand years ago. This is not the first study to find a history of psychedelic use prior to ritual sacrifice, indicating that this may have been a more widespread practice than it was once thought to be.

That’s all for this month’s update. Remember to always test and weigh your drugs and until next time—keep thinking wilder.

Think Wilder is reader-supported. If you enjoyed this month’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

This Month in Psychedelics - January 2022

There’s a lot to catch up on since last month. For starters, Canadians can now request access to psychedelics, a country became the first in Asia to decriminalize cannabis, a study found that hemp may protect against COVID-19, and a U.S. politician smoked a blunt in a campaign ad.

Just like last month’s recap, there is no video recap of this month’s psychedelic news recap up on YouTube. I’ll have another update about some changes coming to my YouTube channel that should hopefully be out later this week on my channel, so make sure you subscribe there if you’d like to be informed about things on that front.

There’s a lot to get through this month, so without further ado, let’s jump into the news:

Policy

Wins

Kicking off the new year on a positive note, Health Canada granted the ability for patients to request special access to illegal psychedelic substances for therapeutic purposes. Each request will be assessed on a case-by-case basis and the treatment option will be reserved for serious treatment-resistant and life-threatening conditions only.

Thailand made history by becoming the first Asian country to decriminalize cannabis. The country’s Narcotics Control Board has already approved the removal of the drug from the ministry’s list of controlled substances and the delisting will go into effect 120 days after being formally signed by the health minister.

Future

A global coalition announced its campaign to internationally reschedule psilocybin mushrooms. The International Therapeutic Psilocybin Rescheduling Initiative is working toward a worldwide policy change that would enable new research into their therapeutic potential.

In a surprising move, the mayor of London appears to be pushing for decriminalizing the possession of small amounts of cannabis by 18 to 24 year-olds. This pilot trial is still in its early stages but it may signal a potential for some progressive drug policy reform to start coming out of England.

There were several huge victories in the drug policy reform movement last year, and there’s no signs of slowing down anytime soon. In fact, there are already more than two dozen states that might relax their laws involving cannabis and psychedelics in 2022. With any luck, this might be the biggest year for drug policy reform we’ve seen yet.

But not everything is going in the right direction. Last week the DEA proposed adding five more psychedelics to Schedule I of the Controlled Substances Act. The substances are: 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT. If this push goes through then they will be subject to the same laws that restrict the possession, distribution, import, export, manufacturing, and research of psychedelics such as LSD, psilocybin, and MDMA.

Industry

While many psychedelic companies are trying to patent as much intellectual property as they can, the Multidisciplinary Association of Psychedelic Studies Public Benefit Corporation (MAPS PBC) published a study featuring an open science approach to synthesizing MDMA. Combined with Usona Institute’s recipe for manufacturing psilocybin that was published in 2020, open science like this will greatly benefit the overall psychedelic industry.

Although many people swear by the amazing transformational experiences they’ve had with classical psychedelics such as LSD and psilocybin mushrooms, psychedelic companies are attempting to develop a wide range of novel psychoactive substances. This is similar to the work Alexander “Sasha” Shulgin did in the 20th century. However, the difference is that Sasha wasn’t attempting to corner the market on the psychedelic substances with the greatest potential return on investment.

Research

Published Studies

A study showing that hemp compounds may have the potential of blocking COVID-19 from entering human cells went viral this month. But before you run out to your nearest dispensary (or dealer) for some flower to cram in your vape, you should know that 1) This research was not conducted directly on humans, and 2) The results were not related to smoking, vaping, or eating weed. Instead, the study found that two specific cannabinoids (CBDA and CBGA) inhibited the reproduction and spread of coronavirus during in vitro lab tests.

A clinical trial testing the use of ketamine therapy to treat alcohol use disorder (AUD) reported positive results. The study found that the treatment—which also featured an AUD-specific form of mindfulness practice—led to a 90% abstinence rate for patients for six months. In addition, the risk of deaths was also reduced by ten times.

The field of microdosing research is still in its earliest stages, and the verdict is still out as to whether it’s actually effective or not. However, another study has found that there may be no difference between microdosing and placebo. More than 50 subjects participated in a double-blind trial exploring whether microdosing psilocybin could lead to improvements in emotional and mental health. There were not any significant differences between the periods when the participants were microdosing and the times they were taking a placebo.

Future Studies

With the opioid crisis getting worse every year and the rate of overdose deaths rising faster than ever before, the U.S. federal government is starting to consider its options for addressing these issues. One future study to keep your eyes on will take a look at using a non-hallucinogenic version of ibogaine for addiction treatment, and the National Institute on Drug Abuse is partnering up with neuroscience startup Delix Therapeutics to conduct the study.

Harm Reduction

Drug checking organizations in New Zealand have detected a dramatic decrease in the amount of eutylone (commonly referred to as “bath salts”) being sold as “MDMA” in the country. The reason for this drop in tainted drugs most likely has to do with the fact that New Zealand embraced the concept of drug checking after legalizing the practice in November.

Miscellaneous

A candidate running for U.S. Senate made a ton of waves when he smoked a blunt in a new campaign ad. Democrat Gary Chambers, who is hoping to be Louisiana’s newest senator, spends the ad’s 37 seconds (which is the amount of time in between each cannabis-related arrest in America) talking about the harms of criminalization. It’s really a must-watch.

Rounding this month’s recap out is a history lesson. New archaeological evidence from Peru indicated that elite members of the Wari Empire consumed hallucinogenic beer-like beverages to power and maintain political control. Similar to the Greek Eleusinian Mysteries, we don’t know everything about what occurred at these parties, but one thing’s for sure—the Waris knew how to throw down!

That’s all for this month’s update. Remember to always test and weigh your drugs and until next time—keep thinking wilder.

Think Wilder is reader-supported. If you enjoyed this month’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

This Week in Psychedelics - 11.19.21

Cannabis

  • U.S. Republicans move to decriminalize marijuana at federal level (Reuters)

  • Germany Set To Legalize Marijuana Nationwide After Major Parties Reach Agreement (Marijuana Moment)

  • Brazil is on The Brink of Medical Cannabis Change (High Times)

  • Is This The First Real Case Of Fentanyl-Tainted Marijuana In The U.S.? (Forbes)

  • Indiana Democratic Party Backs Marijuana Legalization And Pledges 2022 Reform Push (Marijuana Moment)

  • New York Senator Files Bill To Extend Marijuana Equity Benefits To Transgender And Non-Binary People (Marijuana Moment)

  • Straws Lined with THC Could Transform Edibles Industry (High Times)

  • Bipartisan Wisconsin Lawmakers Unveil Marijuana Decriminalization Bill (Marijuana Moment)

  • New study shows no increase in car crash injuries after marijuana legalized (Vancouver Sun)

  • Canadian Groups Gives Free Weed And Edibles To Fight Opioid Abuse (High Times)

  • Marijuana Legalization Attitudes Vary Significantly Within Partisan Coalitions, Pew Survey Shows (Marijuana Moment)

  • Creating a better cannabis cultivation facility while strengthening relationships with third-party testing labs (Marijuana Business Daily)

  • Sturdy Hemp Structures Could be the Future Eco-Building (High Times)

  • Using cannabis in pregnancy linked to aggression and anxiety in children, a study suggests (CNN)

  • Study: Scarification of cannabis seeds, certain disinfectants boost germination rates (Marijuana Business Daily)

LSD

  • MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures (Psilocybin Alpha)

  • Up, Up and Away: The Trippy Tales Behind ‘Flying Over Sunset’ (The New York Times)

  • Is LSD Safe - Latest Research Findings (Drug Science)

  • The LSD Comedown: Navigating the After Effects of Acid (DoubleBlind)

Magic Mushrooms

  • Bill on magic mushrooms aims to make Pa. a national leader in psychedelic research (The Philadelphia Inquirer)

  • NYC Subways Ban Marijuana And Psychedelic Mushroom Ads (Marijuana Moment)

  • Magic Mushrooms, A Love Story (The New Yorker)

  • PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch (Psilocybin Alpha)

  • Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders (Yahoo!)

  • TheraPsil and Imperial College London, McGill University Partner on Psilocybin Study (Truffle Report)

  • Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory (Psilocybin Alpha)

  • Another Life: Foraging for mushrooms and natural psychedelics (The Irish Times)

MDMA

  • World's 'Strongest-Ever' Ecstasy Pill Found in English Nightclub (VICE)

DMT

  • Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study (Yahoo!)

  • Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder (Psilocybin Alpha)

Ayahuasca

  • Is This Phoenix Pastor a Spiritual Shaman or an Ayahuasca Kingpin — or Both? (Phoenix New Times)

  • Ron White’s strange ayahuasca experience, as described on JRE. (Ceng News)

5-MeO-DMT

  • Mike Tyson ‘died’ while tripping on psychedelic toad venom (New York Post)

  • Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form (Business Wire)

Novel Psychoactive Substances

  • New Psychedelic Molecules: What’s in Development? (Truffle Report)

  • New Psychedelic Molecules Part II: Key Industry Players (Truffle Report)

  • Researchers train computers to predict the next designer drugs (ScienceDaily)

  • BetterLife Pharma says pharmacology data on second-generation LSD derivative confirms its projected non-hallucinogenic property (Proactive Investors)

Ketamine

  • Michael J. Fox Foundation Grant Will Fund First Clinical Trial of Ketamine to Treat Depression in People with Parkinson’s Disease (Yale School of Medicine)

  • Warning of ‘wild west’ in depression treatment as UK clinics offer ketamine (The Guardian)

  • Bexson Biomedical Announces Expansion to Treat Major Depression with Wearable Ketamine Formulation (PR Newswire)

  • Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods (Psilocybin Alpha)

DXM

  • Teenagers are ‘robotripping’ in the pursuit of cheap highs, again (Screenshot Media!)

Miscellaneous

  • Jon Hopkins’s Psychedelic Journey to a New Way of Creating Music (The New York Times)

  • "Aharon said it was healing:" How psychedelic therapy was undermined by abuse (Inverse)

  • Psychedelics Use Associated With 55 Percent Decrease In Daily Opioid Consumption, Study Finds (Marijuana Moment)

  • Horizons Conference Reconvenes in NYC to Connect Psychedelic Communities (Lucid News)

  • New Non-Profit Supports Groundbreaking HPPD or ‘Acid Flashback’ Research (Truffle Report)

  • Inside The Race To Create A Two-Hour Psychedelic Therapy Experience (Forbes)

  • Psychedelics Help Heal Childhood Trauma, Study Finds (Benzinga)

  • Psychedelic Bypassing: When Avoidance is Mistaken for Healing (Psychedelics Today)

  • Canadian Biotech Known For Psilocybin And Cannabinoid-Based Medicines In FDA Phase 3 Trial For Bucillamine-Based Oral Covid Treatment (Forbes)

  • Three Decades of Drug Policy Reform Work (Open Society Foundations)

  • A Close Reading of the QAnon Shaman’s Conspiracy Manifesto (Lit Hub)

  • Naropa University Announces Psychedelic-Assisted Therapies Certificate (Tricycle)

  • A New Psychedelic Organization is Merging Shamanism and Science (Lucid News)

  • The Serotonin 5-HT2A Receptor: From Mice to Humans (Psychedelic Science Review)

  • Animals That Eat Psychedelics and Enjoy the Trip (Psychedelic Spotlight)

  • CaaMTech Teams Up With University of Wyoming to Study Psychedelics as Treatments for Addiction (Psilocybin Alpha)

  • MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease (Psilocybin Alpha)

  • Letting people test their drugs will reduce the number of needless deaths (The Independent)

  • The History of Psychedelics: An ancient tradition (Canex)

  • MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test (Psilocybin Alpha)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

Film Review - Psychedelia

A new documentary focusing on the history and science behind psychedelics titled Psychedelia is on the verge of being released soon. Sporting a compact 58-minute run-time, this film clocks in at just under an hour and it provides an easily-digestible, high-level overview of psychedelics for a wide audience, from the uninitiated square all the way to the most seasoned psychonaut.

The film opens with a moving quote that properly sets the tone:

The most beautiful and profound emotion we can experience is the sensation of the mystical. It is the sower of all true science.

-Albert Einstein

The introduction consists of a series of beautiful scenes featuring natural landscapes and voice-overs from people who healed themselves by working with psychedelics. It’s only about a minute long but it’s just enough to give the viewer a glimpse of how transformational these medicines can be when used wisely.

Following the introduction, the documentary launches into the history of psychedelics, from Albert Hofmann’s first intentional acid trip all the way up to the new wave of psychedelic research being conducted in respectable institutions like NYU and Johns Hopkins. Along the way it touches on several monumental psychedelic events, including the coining of the term “psychedelic,” R. Gordon Wasson’s encounters with Maria Sabina, the CIA’s MKUltra experiments, Tim Leary’s impact on the scene, LSD leaking out of the lab and onto the streets, and the re-emergence of psychedelic research with Rick Strassman’s DMT study.

Several experts are featured in the film, including Charles Grob, Julie Holland, Rick Doblin, Katherine MacLean, Matthew Johnson, and Ingmar Gorman. Together, their interviews help paint a complete picture of psychedelics for the audience.

In addition to talking about the psychedelics themselves, the film also gives the viewer a chance to learn more about the people working in the psychedelic field, which often turns out to be both entertaining and enlightening. One good example is Charles Grob’s story about calling his father in the middle of the night to tell him he finally knew what he wanted to do for a career—he wanted to study psychedelics. His father was supportive of Charles’ decision but also cautioned that no one would take him seriously unless he got his credentials. So he did.

Psychedelia also features interviews with a handful of participants from a psilocybin for end-of-life anxiety study that was conducted at NYU. Their personal anecdotes about how psilocybin-assisted psychotherapy helped them are moving and inspirational, and if you’re anything like me then you might shed a tear or two while listening to their stories.

Several threads are sewed together to form a coherent film: a narrative detailing the history and science of psychedelics, explanations and insights from the experts, and the moving stories from the study participants. Like any good documentary, it has a beginning, a middle, and an end, and during the final credits an epilogue provides updates on what happened to some of the people in the film, which ties things up quite nicely.

After watching the whole thing, it’s crystal clear that Psychedelia was created by an adept filmmaker—someone who has obviously put in their 10,000 hours in order to learn the skills needed to create a masterpiece of this magnitude.

That man is Pat Murphy. He started working on the documentary in 2011, when he first heard about the psilocybin for end-of-life anxiety research study at NYU. At the time he was a student at NYU Tisch School of the Arts and so, coupled with an interest in the Grateful Dead (shoutout to all the fellow Deadheads out there!), Timothy Leary, and the 1960s, he decided to begin working on the film.

I liked Psychedelia quite a bit. For one thing, it features a ton of new footage that I hadn’t seen before—and I’ve seen a lot of movies about psychedelics.

Somehow Pat was able to make grainy old footage from way back in the day (for example: scenes from a 1955 CIA film) look fresh and new. And some of the audio recordings are a delight, featuring psychedelic elders like Albert Hofmann, Allen Ginsberg, and Ralph Metzner.

One of the funniest moments in the film (which will likely be overlooked by most viewers, as it is very subtle) occurs when Rick Doblin walks upstairs to a room with lots of paperwork strewn about on a desk where a big green bong is sitting upright, ready for a nice toke.

The documentary is so well-done that it comes across as incredibly professional, which goes a long way if you’re trying to convince a skeptic in your life about the value of psychedelics. In fact, I think this is the best film to introduce people to psychedelics that will give them solid overview of psychedelic history and science. It’s a perfect documentary to show your parents, your friends, or even your therapist if you’d like them to learn more about psychedelics without inundating them with too much information all at once. It’s nicely-paced, covering a lot of ground without rushing through. All in all, it’s a solid film.

Psychedelia is definitely worth a watch whether you are completely psychedelically-naïve or you’re a highly-experienced psychonaut, and while it’s not publicly available for streaming at the time that this blog post is going live, you can sign up for the film’s newsletter to find out how to attend a virtual screening event in the near future.

Pat is partnering up with psychedelic organizations and universities to hold these online events, which include Q&A sessions with the director after the film is screened. There are two events currently on the schedule—one on February 6th with the Psychedelic Society of Minnesota and another on February 11th with the Psychedelia Integration Community that will include Katherine MacLean on the Q&A panel. There’s also an option for universities and colleges to license the film for use in the classroom.

Regardless of when you are able to get a chance to watch Psychedelia, you should definitely put it on your radar and check it out as soon as you have the opportunity. It’s rare to find a documentary that encapsulates the history and science of psychedelics this well.

Disclaimer: I received a free screening copy of this film in exchange for an honest review. However, this is not a sponsored post—all thoughts and opinions expressed here are my own.

This Week in Psychedelics - 12.11.20

ThisWeekinPsychedelics.png

Cannabis

  • Mexican Supreme Court Extends Deadline To Legalize Marijuana As Lawmakers Continue To Advance Bill (Marijuana Moment)

  • House Approves Marijuana Research Bill Days After Voting To Federally Legalize Cannabis (Marijuana Moment)

  • What To Expect From The House Of Representatives’ Passing Of Federal Cannabis Reform (Forbes)

  • Feds’ Post-Election Warning: Marijuana Still Banned For Federal Workers Despite State Legalization (Marijuana Moment)

  • NBA Will Reportedly Not Test Players for Marijuana Next Season (Complex)

  • New Jersey lawmakers agree on recreational marijuana legalization bill (Marijuana Business Daily)

  • Nebraska Senators Will Work To Put Recreational Marijuana On The Ballot In 2022 (Marijuana Moment)

  • 70% in U.S. Support Expunging Marijuana Convictions After Vote to Decriminalize Weed: Poll (Newsweek)

  • Embracing Marijuana Legalization Could Have Offset Democratic Election Losses, Poll Indicates (Marijuana Moment)

  • Dumping CBD Oil On Strawberries Extends Their Shelf Life And Stops Mold Growth, New Study Finds (Marijuana Moment)

  • Why Europe's big cannabis route is so hard to shut (BBC)

  • Majority Of Republican Voters Support House-Passed Marijuana Legalization Bill, Poll Finds (Marijuana Moment)

  • Jay-Z’s Cannabis Brand, Monogram, Launches With $50 Hand-Rolled Joints (Forbes)

LSD

  • Mumbai: ‘Paper weight can’t be counted while quantifying LSD’ (Times of India)

Magic Mushrooms

  • N.J. bill to lessen jail time for ‘magic’ mushrooms moves forward (NJ.com)

  • Canada Will Let Health Care Professionals Legally Use Psychedelic Mushrooms, Health Minister Says (Marijuana Moment)

  • Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms (Globe Newswire)

  • Magic Mushrooms Are Expanding Minds and Advancing an Emerging Field of Science (Discover Magazine)

  • Can the active ingredient in magic mushrooms help treat anxiety? Researchers want to know (The Age)

MDMA

  • MDMA-assisted couples therapy investigated in landmark pilot trial (New Atlas)

DMT

  • Psychedelic drug DMT to be trialled in UK to treat depression (The Guardian)

  • Why Does the Brain Make Its Own DMT? (DoubleBlind)

  • How to Integrate a Difficult-to-Remember DMT Experience (Maps of the Mind)

Ayahuasca

  • Miley Cyrus Says Ayahuasca Changed Her Life (Lucid News)

  • Preserving Entangled Ayahuasca (Chacruna)

5-MeO-DMT

  • Usona Institute Publishes Synthesis and Characterization of cGMP 5-MeO-DMT (Psilocybin Alpha)

Peyote

Novel Psychoactive Substances

  • New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression (UC Davis)

Ketamine

  • PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson’s Disease (Psilocybin Alpha)

  • Mind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy (Psilocybin Alpha)

Miscellaneous

  • Psychedelics Weren't As Common in Ancient Cultures As We Think (VICE)

  • The Top 10 Psychedelic Research Papers of 2020 (Psychedelic Science Review)

  • This Is How Psychedelics Hack the Brain, According to Scientists (VICE)

  • The Case for Macrodosing (Rolling Stone)

  • Psychedelic Guide Abuse: High-Control Group Dynamics and Complicity in the Perpetuation of Harm (Psychedelics Today)

  • UK government set for psychedelics investment windfall (Financial Times)

  • It Takes Guts: Psychedelic Treatment Approaches to Autoimmune Disorders (Psychedelic Science Review)

  • Humans Have Used Drugs With Sex For Millennia – The Reasons Are Much Broader Than You Think (TalkingDrugs)

  • How To Provide Psychedelic Support (Lucid News)

  • Psychedelics, Therapy, and the Law (Psychedelic Frontier)

  • Christopher Valore (AKA The Architect) talks “Conductor,” His Virtual-Reality, Psychedelic-Visual Sandbox Platform (Psymposia)

  • Psychedelics, Shadows, and Spiritual Bypassing (The Third Wave)

  • How Music Therapists Helped Build Psychedelic Therapy (Chacruna)

  • How to Change Your Ability to Change (Psychedelic Science Review)

  • Combining Movement and Microdosing: Athletics, Exercise, and Flow (The Third Wave)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalogue how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.